Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform

Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in the management of this disease stage. However, these therapies come with...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Pawel Rajwa, Angelika Borkowetz, Thomas Abbott, Andrea Alberti, Anders Bjartell, James T. Brash, Riccardo Campi, Andrew Chilelli, Mitchell Conover, Niculae Constantinovici, Eleanor Davies, Bertrand De Meulder, Sherrine Eid, Mauro Gacci, Asieh Golozar, Haroon Hafeez, Samiul Haque, Ayman Hijazy, Tim Hulsen, Andreas Josefsson, Sara Khalid, Raivo Kolde, Daniel Kotik, Samu Kurki, Mark Lambrecht, Chi-Ho Leung, Julia Moreno, Rossella Nicoletti, Daan Nieboer, Marek Oja, Soundarya Palanisamy, Peter Prinsen, Christian Reich, Giulio Raffaele Resta, Maria J. Ribal, Juan Gómez Rivas, Emma Smith, Robert Snijder, Carl Steinbeisser, Frederik Vandenberghe, Philip Cornford, Susan Evans-Axelsson, James N'Dow, Peter-Paul M. Willemse
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-05-01
Serier:	European Urology Open Science
Fag:	Prostate cancer Metastatic Hormone sensitive Docetaxel Androgen receptor signaling inhibitor Big data
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2666168324003331
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!